The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment

Guglielmo Ronco, Silvia Brezzi, Francesca Carozzi, Paolo Dalla Palma, Paolo Giorgi-Rossi, Daria Minucci, Carlo Naldoni, Nereo Segnan, Marco Zappa, Manuel Zorzi, Jack Cuzick

Research output: Contribution to journalArticle

Abstract

Objectives.: To study the impact of different cervical cancer screening strategies including HPV testing. Methods.: A randomised controlled trial with a conventional arm (conventional cytology) and an experimental arm following two phases (first HPV testing + conventional cytology, second HPV testing alone). In phase one, different protocols were applied to different age groups (25-34 and 35-60). Published data on test accuracy during the phase one of recruitment are summarised. Results.: 45,307 women were recruited in phase one (about 95,000 overall). In the age group 35-60, HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off increased sensitivity vs. conventional cytology (relative sensitivity 1.41; 95% CI: 0.98-1.02) with a small loss in Positive Predictive Value (PPV; relative PPV 0.75; 95% CI: 0.45-1.25). Adding liquid-based cytology as screening test and referring to colposcopy women positive to either only marginally increased sensitivity but strongly reduced PPV. In the age group 25-34, similar results (relative sensitivity vs. conventional cytology 1.58; 95% CI: 1.032.44; relative PPV 0.78; 95% CI: 0.72-1.16) were obtained, despite 14% of women were HPV positive, with a strategy based on HPV alone as screening test, triaging HPV positive women by cytology, directly referring those ASCUS+ to colposcopy and repeating both tests after 1 year in those with normal cytology. Conclusions.: HPV testing, if used as screening test, should be applied alone, with cytology triage essential in younger women but preferable at all ages. Follow-up data will allow analysis of the safety of prolonging screening intervals and the relative persistence of lesions detected with different methods.

Original languageEnglish
JournalGynecologic Oncology
Volume107
Issue number1 SUPPL.
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Cell Biology
Randomized Controlled Trials
Technology
Colposcopy
Age Groups
Triage
Safety

Keywords

  • Cervical cancer
  • Cytology
  • HPV
  • RCT
  • Screening

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. / Ronco, Guglielmo; Brezzi, Silvia; Carozzi, Francesca; Dalla Palma, Paolo; Giorgi-Rossi, Paolo; Minucci, Daria; Naldoni, Carlo; Segnan, Nereo; Zappa, Marco; Zorzi, Manuel; Cuzick, Jack.

In: Gynecologic Oncology, Vol. 107, No. 1 SUPPL., 10.2007.

Research output: Contribution to journalArticle

Ronco, G, Brezzi, S, Carozzi, F, Dalla Palma, P, Giorgi-Rossi, P, Minucci, D, Naldoni, C, Segnan, N, Zappa, M, Zorzi, M & Cuzick, J 2007, 'The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment', Gynecologic Oncology, vol. 107, no. 1 SUPPL.. https://doi.org/10.1016/j.ygyno.2007.07.021
Ronco, Guglielmo ; Brezzi, Silvia ; Carozzi, Francesca ; Dalla Palma, Paolo ; Giorgi-Rossi, Paolo ; Minucci, Daria ; Naldoni, Carlo ; Segnan, Nereo ; Zappa, Marco ; Zorzi, Manuel ; Cuzick, Jack. / The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. In: Gynecologic Oncology. 2007 ; Vol. 107, No. 1 SUPPL.
@article{bd543c1568f944739f7d11d11c02ee06,
title = "The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment",
abstract = "Objectives.: To study the impact of different cervical cancer screening strategies including HPV testing. Methods.: A randomised controlled trial with a conventional arm (conventional cytology) and an experimental arm following two phases (first HPV testing + conventional cytology, second HPV testing alone). In phase one, different protocols were applied to different age groups (25-34 and 35-60). Published data on test accuracy during the phase one of recruitment are summarised. Results.: 45,307 women were recruited in phase one (about 95,000 overall). In the age group 35-60, HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off increased sensitivity vs. conventional cytology (relative sensitivity 1.41; 95{\%} CI: 0.98-1.02) with a small loss in Positive Predictive Value (PPV; relative PPV 0.75; 95{\%} CI: 0.45-1.25). Adding liquid-based cytology as screening test and referring to colposcopy women positive to either only marginally increased sensitivity but strongly reduced PPV. In the age group 25-34, similar results (relative sensitivity vs. conventional cytology 1.58; 95{\%} CI: 1.032.44; relative PPV 0.78; 95{\%} CI: 0.72-1.16) were obtained, despite 14{\%} of women were HPV positive, with a strategy based on HPV alone as screening test, triaging HPV positive women by cytology, directly referring those ASCUS+ to colposcopy and repeating both tests after 1 year in those with normal cytology. Conclusions.: HPV testing, if used as screening test, should be applied alone, with cytology triage essential in younger women but preferable at all ages. Follow-up data will allow analysis of the safety of prolonging screening intervals and the relative persistence of lesions detected with different methods.",
keywords = "Cervical cancer, Cytology, HPV, RCT, Screening",
author = "Guglielmo Ronco and Silvia Brezzi and Francesca Carozzi and {Dalla Palma}, Paolo and Paolo Giorgi-Rossi and Daria Minucci and Carlo Naldoni and Nereo Segnan and Marco Zappa and Manuel Zorzi and Jack Cuzick",
year = "2007",
month = "10",
doi = "10.1016/j.ygyno.2007.07.021",
language = "English",
volume = "107",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment

AU - Ronco, Guglielmo

AU - Brezzi, Silvia

AU - Carozzi, Francesca

AU - Dalla Palma, Paolo

AU - Giorgi-Rossi, Paolo

AU - Minucci, Daria

AU - Naldoni, Carlo

AU - Segnan, Nereo

AU - Zappa, Marco

AU - Zorzi, Manuel

AU - Cuzick, Jack

PY - 2007/10

Y1 - 2007/10

N2 - Objectives.: To study the impact of different cervical cancer screening strategies including HPV testing. Methods.: A randomised controlled trial with a conventional arm (conventional cytology) and an experimental arm following two phases (first HPV testing + conventional cytology, second HPV testing alone). In phase one, different protocols were applied to different age groups (25-34 and 35-60). Published data on test accuracy during the phase one of recruitment are summarised. Results.: 45,307 women were recruited in phase one (about 95,000 overall). In the age group 35-60, HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off increased sensitivity vs. conventional cytology (relative sensitivity 1.41; 95% CI: 0.98-1.02) with a small loss in Positive Predictive Value (PPV; relative PPV 0.75; 95% CI: 0.45-1.25). Adding liquid-based cytology as screening test and referring to colposcopy women positive to either only marginally increased sensitivity but strongly reduced PPV. In the age group 25-34, similar results (relative sensitivity vs. conventional cytology 1.58; 95% CI: 1.032.44; relative PPV 0.78; 95% CI: 0.72-1.16) were obtained, despite 14% of women were HPV positive, with a strategy based on HPV alone as screening test, triaging HPV positive women by cytology, directly referring those ASCUS+ to colposcopy and repeating both tests after 1 year in those with normal cytology. Conclusions.: HPV testing, if used as screening test, should be applied alone, with cytology triage essential in younger women but preferable at all ages. Follow-up data will allow analysis of the safety of prolonging screening intervals and the relative persistence of lesions detected with different methods.

AB - Objectives.: To study the impact of different cervical cancer screening strategies including HPV testing. Methods.: A randomised controlled trial with a conventional arm (conventional cytology) and an experimental arm following two phases (first HPV testing + conventional cytology, second HPV testing alone). In phase one, different protocols were applied to different age groups (25-34 and 35-60). Published data on test accuracy during the phase one of recruitment are summarised. Results.: 45,307 women were recruited in phase one (about 95,000 overall). In the age group 35-60, HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off increased sensitivity vs. conventional cytology (relative sensitivity 1.41; 95% CI: 0.98-1.02) with a small loss in Positive Predictive Value (PPV; relative PPV 0.75; 95% CI: 0.45-1.25). Adding liquid-based cytology as screening test and referring to colposcopy women positive to either only marginally increased sensitivity but strongly reduced PPV. In the age group 25-34, similar results (relative sensitivity vs. conventional cytology 1.58; 95% CI: 1.032.44; relative PPV 0.78; 95% CI: 0.72-1.16) were obtained, despite 14% of women were HPV positive, with a strategy based on HPV alone as screening test, triaging HPV positive women by cytology, directly referring those ASCUS+ to colposcopy and repeating both tests after 1 year in those with normal cytology. Conclusions.: HPV testing, if used as screening test, should be applied alone, with cytology triage essential in younger women but preferable at all ages. Follow-up data will allow analysis of the safety of prolonging screening intervals and the relative persistence of lesions detected with different methods.

KW - Cervical cancer

KW - Cytology

KW - HPV

KW - RCT

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=34748818225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748818225&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.07.021

DO - 10.1016/j.ygyno.2007.07.021

M3 - Article

C2 - 17822751

AN - SCOPUS:34748818225

VL - 107

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1 SUPPL.

ER -